University-Mayo Grants Awarded to Advance Research Projects With Commercialization Potential
Two research teams have been awarded up to $50,000 each to pursue health research projects that have the potential to lead to a start-up company or license agreement. If successful, the University of Minnesota and Mayo Clinic grantees will be eligible to apply for up to $400,000 in additional funding.
Awardees received funding through the Translational Product Development Fund (TPDF), which supports the development of novel therapeutic compounds, devices, diagnostics, or IT products with commercial potential.
The grant program is a collaboration between CTSI’s Office of Discovery and Translation and the Mayo Clinic Center for Clinical and Translational Science (CCaTS) in conjunction with the Minnesota Partnership for Biotechnology and Medical Genomics (MNP).
By translating research discoveries into new therapies and treatment approaches for patients, the Translational Product Development Fund aims to impact the lives of Minnesotans.
The program awarded grants to the following projects and investigators:
Anastomotic BRIDGE (Buttressing Reinforced In-line Device Generating Epithelialization) Porcine Lab
- Shanda Blackmon, MD, MPH, Mayo Clinic
- Rafael Andrade, MD, Department of Surgery, University of Minnesota
Ambulatory Noninvasive Measurement of Potassium in Patients with Cardiac and Renal Disease to Prevent Rehospitalization
- Grace Lin, MD, Mayo Clinic
- Paul Friedman, MD, Mayo Clinic
Proposals were evaluated based on clinical need/impact, project feasibility and expertise, and commercialization potential.
The program’s next RFA will be issued in early 2017.
Funding for projects involving human research subjects is contingent on approval from the NIH's National Center for Advancing Translational Sciences.